Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

COPD Clinical Trial

Official title:

A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of ZofinTM for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT05643729
• Other study ID #: 27198
• Status: Suspended
• Phase: Phase 1/Phase 2
• Start date: November 15, 2023
• Est. completion date: August 31, 2024

Study information

• Verified date: October 2022
• Source: Organicell Regenerative Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion (IV) of Zofin for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).

Description:

Total of 20 adult patients will be chosen from population of adults between the age of 40 to 80 diagnosed with COPD to be randomized to 1 of 2 treatment arms including IV infusion of Zofin or IV infusion on sterile saline. The subjects will be followed for 12 months to demonstrate safety and efficacy of Zofin.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 20
• Est. completion date: August 31, 2024
• Est. primary completion date: May 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject who can understand and are able to provide informed consent.
• Subject with moderate to severe COPD with normal cardiac, liver and renal function
• Subject must have a post-bronchodilator FEV1/FVC ratio of less than 0.7
• Subject must have a post-bronchodilator FEV1 percent predicted value <50%
• Subject must have a RV/TLC ratio of > 40%
• Subject must be either a non-smoker or an ex-smoker, with a cigarette smoking history of = 10 packs per year.
• Subject must have abstained from nicotine products for at least six months prior to enrollment in the study.
• Subject must be available for all specified assessments at the study site through the completion of the study.
• Subject must have oxyhemoglobin saturation on room air at rest equal or greater than 88% without oxygen
• Subject must be reasonably able to return for multiple follow-up visits.
• Adequate venous access
• For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment.
• Any male subject must agree to use contraceptives and not donate sperm during the study.

Exclusion Criteria:

• Subject with clinically significant illness with manifestations of significant organ dysfunction which in the judgment of the PI or co-investigator would render the study subject unlikely to tolerate the infusion or complete the study
• Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.
• Subject has been diagnosed with a pulmonary disease other than COPD (e.g. asthma, pulmonary, fibrosis, sarcoidosis, pulmonary hypertension, bronchiolitis, interstitial lung disease)
• Subject has been diagnosed with a1-Antitrypsin deficiency
• Subject has a body mass index greater than 42 kg/m2
• Subject has or had an active infection requiring systemic antibiotics within 12 weeks on enrollment in the study
• Subject has or had exacerbation of COPD requiring hospitalization within 12 weeks of enrollment in the study.
• Subject has initiated pulmonary rehabilitation within 12 weeks of enrollment in the study
• Subject uses or used prednisone (or equivalent dose of another corticosteroid) within 12 weeks of enrollment in the study
• Subject has evidence or history of malignancy
• Subject has evidence or history of autoimmune disorders independent of COPD
• Subject is pregnant or breast-feeding
• Subject with pulmonary lobectomy or lung volume reduction surgery or lung transplantation. Subject with clinically significant bronchiectasis.
• Subject received an experimental therapy (drug or biologic) for any indication within 12 months of the study enrollment.
• Subject is unable to complete all the testing required for the study
• Subject who is on immunosuppressive medications.
• Subject who is unwilling to stop taking prescription or over the counter pain medication for 7 days prior to any visit.
• Subject with a history of bleeding disorders, anticoagulation therapy that cannot be stopped as prior to infusion.
• Active listing (or expected future listing) for transplant of any organ.
• Be a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.
• History of drug abuse (illegal "street" drugs) except noninhalation use of marijuana (If it is legal use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (= 5 drinks/day for ? 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs withinthe past 24 months. Use of inhalation marijuana will be an exclusion criterion.
• Subject with untreated HIV infection. However, patients can be enrolled if they have been treated for HIV and test negative for HIV viral load but still test positive for antibodies.

Related Conditions & MeSH terms

• COPD
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Zofin
Intravenous Infusion (IV) of Zofin

Other:
• Placebo
Intravenous Infusion of sterile saline

Locations

Country	Name	City	State
United States	Mayo Clinic	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Organicell Regenerative Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of Zofin	To demonstrate the safety of Zofin administered intravenously in subjects with COPD by measuring incidence of any of the following treatment-emergent serious adverse events (TE-SAEs) within the first 30 days of infusion: Life-threatening event (e.g., stroke or non-fatal pulmonary embolism).; Event requiring inpatient hospitalization or prolongation of existing hospitalization (e.g., for worsening dyspnea).; Event resulting in persistent or significant disability/incapacity.; Event resulting in death. Frequency and severity of any adverse events from Day 0 (day of treatment) up to 12 months of treatment will similarly be observed.	first 30 days
Primary	Safety of Zofin	To monitor the frequency and severity of adverse events	day 0 to 12 months
Secondary	FVC	FVC from resting PFT	Screen, day 4, day 8, 4 months, 8 months and 12 months
Secondary	FEV1	FEV1 from resting PFT	Screen, day 4, day 8, 4 months, 8 months and 12 months
Secondary	FEV1 to FVC ratio	FEV1 to FVC ratio on resting pulmonary function test	Screen, day 4, day 8, 4 months, 8 months and 12 months
Secondary	FEF25-75	FEF25-75 on resting pulmonary function test	Screen, day 4, day 8, 4 months, 8 months and 12 months
Secondary	Lung Volume Changes	Change in lung volumes (in body plethysmograph), including SGAW (specific airway conductance) and RV (to calculate gas trapping)	Screen, day 4, day 8, 4 months, 8 months and 12 months
Secondary	DLCO	Change in single breath diffusing capacity of lung for carbon monoxide (DLCO)	Screen, day 4, day 8, 4 months, 8 months and 12 months
Secondary	HU of CT Scan	Change in the average of Hounsfield Unit (HU) - a relative quantitative measurement of radio density in CT images.	Screen and 12 months
Secondary	% air in lung on CT Scan	Change in the percentage of air in the lung	Screen and 12 months
Secondary	CPET	Cardiopulmonary Exercise Testing (CPET) with peak VO2 and measures of dynamic hyperinflation	Screen, 4 months, and 12 months
Secondary	Peak VO2	Cardiopulmonary Exercise Testing (CPET) with peak VO2	Screen, 4 months, and 12 months
Secondary	Dynamic Hyperinflation	Cardiopulmonary Exercise Testing (CPET) with measures of dynamic hyperinflation	Screen, 4 months, and 12 months
Secondary	Pulmonary Exacerbation	Incidence of investigator-defined pulmonary exacerbation: decrease in exacerbation-related hospitalization	Screening through 12 months
Secondary	TNF-a	Change in serum inflammatory markers: TNF-a	Day 0, Day14, 4 months, 8 months, and 12 months
Secondary	CRP	Change in serum inflammatory markers: CRP	Day 0, Day14, 4 months, 8 months, and 12 months
Secondary	IL-1	Change in serum inflammatory markers: IL-1	Day 0, Day14, 4 months, 8 months, and 12 months
Secondary	D-Dimer	Change in serum inflammatory markers: D-dimer	Day 0, Day14, 4 months, 8 months, and 12 months
Secondary	Fibrinogen	Change in serum inflammatory markers: Fibrinogen	Day 0, Day14, 4 months, 8 months, and 12 months
Secondary	SF-36 ot SGRQ	Change in SF-36 questionnaire or St. George's Respiratory Questionnaire (SGRQ)	Screen, 14 days, 1.5 months, 4 months, 8 months, and 12 months
Secondary	CAT Assessment	Change in quality of life (QOL) assessments via COPD Assessment Test (CAT)	Screen, 14 days, 1.5 months, 4 months, 8 months, and 12 months